First Trust Direct Indexing L.P. Cuts Position in Genmab A/S (NASDAQ:GMAB)

First Trust Direct Indexing L.P. decreased its holdings in Genmab A/S (NASDAQ:GMAB) by 42.6% in the 4th quarter, HoldingsChannel reports. The fund owned 9,045 shares of the company’s stock after selling 6,709 shares during the quarter. First Trust Direct Indexing L.P.’s holdings in Genmab A/S were worth $288,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of GMAB. NewEdge Wealth LLC boosted its stake in shares of Genmab A/S by 50.7% during the fourth quarter. NewEdge Wealth LLC now owns 119,989 shares of the company’s stock valued at $3,820,000 after acquiring an additional 40,382 shares during the last quarter. Keybank National Association OH acquired a new position in shares of Genmab A/S during the third quarter worth $1,154,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Genmab A/S by 350.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,845 shares of the company’s stock valued at $154,000 after purchasing an additional 3,770 shares during the period. Knights of Columbus Asset Advisors LLC boosted its stake in shares of Genmab A/S by 16.8% in the third quarter. Knights of Columbus Asset Advisors LLC now owns 5,712 shares of the company’s stock valued at $201,000 after purchasing an additional 822 shares during the period. Finally, Northern Trust Corp boosted its stake in shares of Genmab A/S by 83.3% in the third quarter. Northern Trust Corp now owns 559,044 shares of the company’s stock valued at $19,717,000 after purchasing an additional 254,042 shares during the period. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Trading Up 0.9 %

NASDAQ:GMAB opened at $29.29 on Wednesday. Genmab A/S has a twelve month low of $26.32 and a twelve month high of $42.72. The company has a 50-day moving average of $29.39 and a 200-day moving average of $29.88. The firm has a market cap of $19.37 billion, a price-to-earnings ratio of 24.41, a price-to-earnings-growth ratio of 2.13 and a beta of 1.00.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Wednesday, February 14th. The company reported $0.36 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.02. Genmab A/S had a net margin of 30.74% and a return on equity of 18.90%. The company had revenue of $675.29 million during the quarter, compared to analyst estimates of $678.14 million. On average, research analysts forecast that Genmab A/S will post 1.06 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Morgan Stanley restated an “underweight” rating on shares of Genmab A/S in a research note on Tuesday, March 26th. HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a research note on Tuesday, April 30th. Truist Financial restated a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a research note on Tuesday, March 26th. BMO Capital Markets upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $46.00 to $48.00 in a research note on Friday, February 23rd. Finally, Citigroup downgraded shares of Genmab A/S from a “neutral” rating to a “sell” rating in a research note on Monday, January 22nd. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $48.50.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.